TITLE:
Study on Analgesia and Sedation of Butorphanol Tartrate Combined with Dexmedetomidine in Severe Cerebral Hemorrhage for Patients with Mechanical Ventilation
AUTHORS:
Gang Yang, Shaojun Yang, Chenbing Wang
KEYWORDS:
Butorphanol Tartrate, Dexmedetomidine, Severe Cerebral Hemorrhage, Mechanical Ventilation, Analgesia and Sedation
JOURNAL NAME:
Advances in Bioscience and Biotechnology,
Vol.13 No.10,
October
17,
2022
ABSTRACT: Objective: To
analyze the effect and advantages in analgesia and sedation of butorphanol
tartrate combined with dexmedetomidine in severe cerebral hemorrhage for
patients with mechanical ventilation. Methods: 120 patients with severe
cerebral hemorrhage requiring analgesia and sedation were randomly selected and
divided into two groups: the control group (dexmedetomidine treatment group)
and the test group (dexmedetomidine combined with butorphanol tartrate). Two
groups of patients with different drugs were analyzed. Results: The
average dose of dexmedetomidine (microgram) and the total adverse events
(Times) in the test group were significantly lower than those in the control
group within 48 hours (P Conclusion: Using butorphanol tartrate
combined with dexmedetomidine can achieve the same sedative effect and enhance
the analgesic effect as using dexmedetomidine alone with less dose of
dexmedetomidine, and the clinical effect is significant. It also solves the
problem that adverse reactions such as blood pressure change and bradycardia
are easy to occur when using large dose of dexmedetomidine and the infusion speed
is fast in clinical application, and significantly reduces the incidence of
adverse reactions. It is worthy of clinical application.